1 Table of Contents 1 Table of Contents 2 2 Introduction 3 2.1 Report Guidance 4 3 Marketed Products 5 3.1 Levodopa-plus-Carbidopa-Based Treatments 5 3.2 Dopamine Agonists 7 3.3 Monoamine Oxidase-B Inhibitors 9 3.4 Catechol-O-methyltransferase Inhibitors 10 3.5 Alternative Treatments 11 4 Pipeline Products 14 4.1 Changes to Levodopa-plus-Carbidopa-Based Treatment, 2016–2022 14 4.2 Changes to Alternative Treatments, 2016–2022 15 5 Appendix 17 5.1 Abbreviations 17 5.2 References 17 5.3 Research Methodology 20 5.4 Contact Us 20 5.5 Disclaimer 20